Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity
- PMID: 21687032
- PMCID: PMC3027076
- DOI: 10.1136/bcr.01.2009.1411
Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity
Abstract
Myositis in HIV may be due to HIV itself, or to opportunistic infection, malignancy or drug treatment. Severe myositis or rhabdomyolysis have never been reported with the commonly used nucleoside reverse transcriptase inhibitor abacavir, although creatine phosphokinase may rise modestly, particularly if abacavir hypersensitivity occurs. We report an unusual case of abacavir use associated with a thousand-fold rise in creatine phosphokinase in the absence of features of hypersensitivity. The case was also notable firstly in that there was an absence of the HLA-B5701 allele, the most common human leucocyte antigen (HLA) allele associated with hypersensitivity, and, secondly, as the case occurred in an African patient, African people not being prone to abacavir hypersensitivity.
Figures
References
-
- Vivino G, Antonelli M, Moro ML, et al. Risk factors for acute renal failure in trauma patients. Intensive Care Med 1998; 24: 808–14 - PubMed
-
- Zell S. Clinical correlates to muscle biopsy findings in HIV patients experiencing fatigue: a case series. J Int Assoc Physicians AIDS Care 2002; 1: 90–4 - PubMed
-
- Biviji AA, Paiement G, Steinbach L. Musculoskeletal manifestations of HIV infection. J Am Acad Orthop Surg 2002; 10: 312–20 - PubMed
-
- Whitfield MJ, Kaveh S, Koehler JE, et al. Bacillary angiomatosis associated with myositis in a patient infected with HIV. Clin Infect Dis 1997; 24: 562–4 - PubMed
LinkOut - more resources
Full Text Sources
Research Materials